TrialThe Lancet. Infectious diseases2021

Safety and immunogenicity of an inactivated SARS-CoV-2 vaccine, BBV152: interim results from a double-blind, randomised, multicentre, phase 2 trial, and 3-month follow-up of a double-blind, randomised phase 1 trial.

Raches Ella et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.